| Literature DB >> 31472910 |
Rachel M Lee1, Shishir K Maithel2.
Abstract
Distal cholangiocarcinoma is a rare malignancy with a dismal prognosis. Because of its location and aggressive nature, patients often present with locally advanced or metastatic disease, and effective treatment options are limited. For patients with resectable disease, surgery is the only chance for cure, but achieving an R0 resection is paramount. Optimal adjuvant therapy in resectable disease remains under investigation. Randomized controlled trials investigating neoadjuvant therapy and its impact on resectability and long-term outcomes are needed to continue to improve the outcomes of patients with distal cholangiocarcinoma.Entities:
Keywords: Adjuvant therapy; Distal cholangiocarcinoma; Extrahepatic cholangiocarcinoma; Risk factors; Surgery
Mesh:
Year: 2019 PMID: 31472910 DOI: 10.1016/j.soc.2019.06.014
Source DB: PubMed Journal: Surg Oncol Clin N Am ISSN: 1055-3207 Impact factor: 3.495